XSHE
300966
Market cap424mUSD
Oct 09, Last price
24.75CNY
1D
0.53%
1Q
-17.86%
IPO
-41.13%
Name
Hubei Goto Biopharm Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hubei Goto Biopharm Co.,Ltd. is a Chinese enterprise specializing in the manufacture and distribution of active pharmaceutical ingredients (APIs) and intermediate compounds for steroid hormones. Its product line features essential starting materials such as 9a-hydroxy-4-androstenedione (9a-OHAD), bisnoralcohol (BA), sitolactone, 1,4-androstadienedione (ADD), and 4-androstenedione (4-AD). The company also provides a variety of intermediates, including those for estrogens, progesterone, non-steroidal substances, various other hormones, and corticosteroids. Furthermore, Hubei Goto Biopharm supplies additional raw materials for the pharmaceutical industry. The firm was established in Yicheng, China, in 2006.
Key people
Wenjing Chen
Deputy General Manager, Secretary of the Board · since 2018
Minglei Li
Deputy General Manager, Director · since 2008
Xiangdong Liu
Chief Financial Officer, Director · since 2018
Xueming Wang
Director · since 2021
Zubin Xi
Chairman of the Board, General Manager, Director of R&D · since 2021
Deliang He
Independent Director · since 2024
Independent Director · since 2024
Independent Director · since 2024
Headquarters & legal address
湖北省宜城市小河镇高坑一组
宜昌市, HB 441400
CN
宜昌市, HB 441400
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||